B. Riley lowered the firm’s price target on Kymera Therapeutics (KYMR) to $38 from $41 and keeps a Neutral rating on the shares following the Q1 report. The firm cites the TYK2 discontinuation for the target cut.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics: Innovative Approaches in Autoimmune Disease Treatment Drive Buy Rating
- Kymera Therapeutics price target lowered to $55 from $60 at BTIG
- Kymera Therapeutics price target lowered to $44 from $47 at BofA
- Kymera Therapeutics: Hold Rating Amid Uncertainty in KT-621 and Strategic Shifts
- Kymera Therapeutics: Promising Pipeline Developments and Strategic Decisions Support Buy Rating